Volitionrx Ltd (New York Stock Exchange Arca:VNRX)
| Market Cap | $1.95M-97.5% |
| Revenue (ttm) | $3.44M+134.0% |
| Net Income | -$24.06M-5.2% |
| EPS | -$3.08+34.0% |
| Shares Out | 12.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,200,851 |
| Open | $0.17 |
| Previous Close | $0.16 |
| Day's Range | $0.16 - $0.17 |
| 52-Week Range | $0.16 - $7.80 |
| Beta | 1.16 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Mar 30, 2027 |
About VNRX
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 30, 2027Earnings report
$VNRX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in VNRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VNRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VNRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New VNRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VNRX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in VNRX
| VXFVanguard Extended Market ETF | $9.90K |
| STSBiShares Factors US Small Blend Style ETF | $615.59 |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from VNRX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Strong Q3 earnings beat with 157% revenue surge, clinical validation progress, and expanded commercial partnerships signal positive momentum and growth execution.
